USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/11837
Full metadata record
DC FieldValueLanguage
dc.contributor.authorManoli, Rahela
dc.date.accessioned2020-09-30T14:53:34Z
dc.date.available2020-09-30T14:53:34Z
dc.date.issued2016
dc.identifier.citationMANOLI, Rahela. Biomarkers in ovarian cancer. In: MedEspera: the 6th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2016, p. 252.en_US
dc.identifier.isbn978-9975-3028-3-8.
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/11837
dc.descriptionDepartament of Biochemistry and clinical Biochemistry, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, The 6th International Medical Congress for Students and Young Doctorsen_US
dc.description.abstractIntroduction: Elucidation of the most frequent biomarkers in ovarian cancer. Materials and methods: The study was based on the analysis of biographical sources from 2007- 2014. Discussion results: One of the major challenges in cancer research is the identification of stable biomarkers, which can be routinely measured noninvasively in easily accessible samples. Ovarian cancer is one such disease that would benefit from improved diagnostic markers. Ovarian cancer is the leading cause of death from gynecological malignancy in the western world. One way to facilitate early detection of ovarian cancer is through screening, but currently available diagnostic tools, including ovarian cancer biomarkers and clinical imaging, lack sufficient specificity and sensitivity for implementation in a population-based screening program. Conclusions: The ability to sensitively and specifically predict the presence of early disease and its status, stage and Associated therapeutic efficacy has the potential to revolutionize ovarian cancer detection and treatment and to greatly improve the quality of life and survival rates of ovarian cancer patients.en_US
dc.language.isoenen_US
dc.publisherMedEsperaen_US
dc.subjectovarian canceren_US
dc.subjectdiagnosisen_US
dc.subjectbiomarkeren_US
dc.subjectearly detectionen_US
dc.titleBiomarkers in ovarian canceren_US
dc.typeArticleen_US
Appears in Collections:MedEspera 2016

Files in This Item:
File Description SizeFormat 
Biomarkers_in_ovarian_cancer.pdf261.85 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback